Arch Biopartners, Inc. · TSXV:ARCH
Arch Biopartners — Investor Presentation (May 2026)
28 slides from Arch Biopartners's investor presentation, May 2026
Slide 1: New Drugs for Acute Kidney Injury and Chronic Kidney Disease
TSXV: ARCH.V OTCQB: ACHFF.US New Drugs for Acute Kidney Injury and Chronic Kidney Disease May 2026 www.archbiopartners.com
Slide 2: Notes about forward-looking statements
Notes about forward-looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates
Slide 3: A critical gap in kidney treatment
A critical gap in kidney treatment Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) affect millions of people, with limited drug treatment options available. Patients with kidney failure must undergo dialysis while waiting for a kidney transplant in order to survive. Arch Biopartners is pi
Slide 4: Global scale and clinical burden of kidney disease
Global scale and clinical burden of kidney disease Millions face acute and chronic kidney disease every year. Acute Kidney Injury (AKI) Chronic Kidney Disease (CKD) ■ Affects approximately 13 million people ■ More than 800 million people globally have globally each year, with a significant burden chr
Slide 5: A dual-platform approach to kidney disease
A dual-platform approach to kidney disease Arch Biopartners is developing novel, on-target drug candidates for acute kidney injury (AKI) and chronic kidney disease (CKD). Two drugs in Phase II trials to prevent AKI: Next-generation drugs for diabetic kidney ■ LSALT peptide (Phase II) – Targeting dis
Slide 6: LSALT peptide
LSALT peptide Targeting acute inflammation in the kidneys. MAY 2026 • www.archbiopartners.com • SLIDE 6
Slide 7: LSALT peptide is in a Phase II trial to protect kidneys from cardiac surgery-associated AKI
LSALT peptide is in a Phase II trial to protect kidneys from cardiac surgery-associated acute kidney injury (CS-AKI). Up to 30% of cardiac surgery (CS) patients on bypass machines experience acute kidney injury (AKI).3,4 ■ Over one million cardiac surgeries, including ■ Phase II trial, designed for
Slide 8: DPEP1: A therapeutic target for acute kidney injury
DPEP1: A therapeutic target for acute kidney injury. Arch’s AKI programs share a common biological target: dipeptidase-1 (DPEP1). LSALT peptide is intended to reduce inflammation-driven injury by inhibiting DPEP1’s role in leukocyte recruitment to the kidney, while cilastatin is intended to reduce to
Slide 9: LSALT peptide targets Dipeptidase-1 (DPEP1)
LSALT peptide targets Dipeptidase-1 (DPEP1). A novel mechanism to block kidney inflammation. In a 2019 Cell publication, Arch scientists reported that DPEP1 mediates white blood cell adhesion in the kidney, driving inflammation and AKI. The published data show that DPEP1 inhibition by LSALT peptide re
Slide 10: Peer-reviewed data in Science Advances shows LSALT peptide blocking the DPEP1 pathway
Peer-reviewed data in Science Advances shows LSALT peptide blocking the DPEP1 pathway to prevent kidney inflammation in mouse kidney models. LSALT peptide reduced ischemia-reperfusion injury (IRI), an inflammation-driven form of AKI, supporting advancement to human clinical studies.18 Intravital Kidne
Slide 11: Previous Phase II trial confirms DPEP1 targeting and inflammation reduction
Previous Phase II trial confirms DPEP1 targeting and inflammation reduction. Biomarker results show a signal of reduced inflammation. Arch scientists’ 2024 BMJ Open publication reported results from a Phase II placebo-controlled trial of LSALT peptide in hospitalized patients. LSALT peptide demonstrate
Slide 12: Cilastatin
Cilastatin Preventing kidney injury caused by toxic pharmaceutical drugs. MAY 2026 • www.archbiopartners.com • SLIDE 12
Slide 13: Cilastatin: a repurposed DPEP1 inhibitor now in Phase II for drug toxin-induced AKI
Cilastatin: a repurposed DPEP1 inhibitor developed by Merck with a long safety record, now in Phase II for drug toxin-induced AKI. Drug toxin-induced AKI is a common complication of widely used antibiotics, chemotherapy, and other nephrotoxic drugs, with no approved treatments. The Phase II PONTiAK
Slide 14: Cilastatin as a treatment for drug toxin-induced AKI
Cilastatin as a treatment for drug toxin-induced AKI. Cilastatin has been shown to inhibit toxin uptake by kidney cells, a mechanism that may help prevent AKI caused by widely used antibiotics, chemotherapy drugs, and contrast agents used in medical imaging. Laboratory studies published in the Journ
Slide 15: Cilastatin is an enzymatic DPEP1 inhibitor that blocks endothelial and tubular DPEP1
Cilastatin is an enzymatic DPEP1 inhibitor that blocks both endothelial and tubular DPEP1 in the kidney. Cilastatin helps prevent toxin-related AKI by stopping the reabsorption of toxins and heme pigments, such as those seen in rhabdomyolysis or drug-induced injury. By blocking DPEP1 on both kidney
Slide 16: Chronic kidney disease (CKD) platform
Chronic kidney disease (CKD) platform Targeting IL-32, a novel lipid droplet-associated cytokine linked to diabetic kidney disease. MAY 2026 • www.archbiopartners.com • SLIDE 16
Slide 17: A next-generation drug platform for chronic kidney disease (CKD)
A next-generation drug platform for chronic kidney disease (CKD). Arch’s CKD platform targets interleukin-32 (IL-32), a human cytokine implicated in kidney inflammation and diabetic kidney disease (DKD). IL-32 has been identified as a potential mediator of lipid droplet accumulation and chronic inflamm
Slide 18: Early research identified IL-32 as a lipid-associated cytokine driving DKD
Early research identified IL-32 as a lipid-associated cytokine driving inflammation and injury in diabetic kidney disease (DKD). IL-32 was first identified as a potential mediator of lipid droplet accumulation and inflammation in DKD in findings presented at Kidney Week 2024 and published in the JASN Abst
Slide 19: Interleukin-32 (IL-32) as a novel driver of diabetic kidney disease
Interleukin-32 (IL-32) as a novel driver of diabetic kidney disease (DKD). Peer-reviewed findings published in Inflammation Research (February 2026) reveal new mechanistic insights into IL-32’s role in DKD, based on research led by Arch Biopartners scientists. Studies of human kidney tissue show that
Slide 20: About Arch Biopartners
About Arch Biopartners Advancing an integrated program with new treatments targeting inflammation- and toxin-related kidney injury. MAY 2026 • www.archbiopartners.com • SLIDE 20
Slide 21: Arch's leadership in kidney therapeutics is protected by strong patents
Arch’s leadership in kidney therapeutics is protected by strong patents. LSALT peptide Cilastatin CKD Platform Composition and Method-of-use patents Patents covering both method-of-use patents. to repurpose cilastatin composition and Approval for the CS-AKI as a treatment to prevent method-of-use fo
Slide 22: Next steps: Advancing three drug programs for acute and chronic kidney injury
Next steps: Advancing three drug programs for acute and chronic kidney injury Arch is advancing two Phase II programs in AKI and an IL-32 CKD platform toward lead optimization and IND planning. The LSALT peptide and cilastatin Phase II trials Arch’s IL-32 CKD platform is advancing a address distinct
Slide 23: Investor Information
Investor Information Visit archbiopartners.com/investor-hub to read the latest Latest news highlights, read and subscribe online. news releases, financial reports, and filings (also at SEDAR+). April 30, 2026 Capitalization Royal Columbian Hospital May 20, 2026 Common shares outstanding: begins patien
Slide 24: Executive Management
Executive Management Richard Muruve Andrew Bishop Dr. Daniel Muruve MD CEO, Director, Co-founder CFO, Director CSO, Co-Founder Mr. Muruve co-founded the Financial executive with A Professor in the Dept. of company with the Arch 20+ years in biotech and Medicine at the University of Inflammation team
Slide 25: A committed board, strategic advisors and scientific leaders
A committed board, strategic advisors and scientific leaders. Patrick Vink, Chair, Director Farris Smith, Strategic Advisor Patrick Vink, M.D., M.B.A., has been an President, Vimy Pharma, Former CFO, Leo advisor to the pharmaceutical industry since Pharma (North America), Novo Nordisk Canada. 2015 an
Slide 26: Contact us for more information
Contact us for more information. Contact us Latest news releases +1 647 428-7031 office archbiopartners.com/investor-hub/press-releases info@archbiopartners.com X (Twitter) About the company https://x.com/archbiopartners archbiopartners.com/about-us LinkedIn Investor information https://bit.ly/ArchBio
Slide 27: Sources
Sources 1. Sawhney, S., et al. Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations. Kidney International, Volume 101, Issue 6, 1271 - 1281. https://doi.org/10.1016/j.kint.2022.02.033 2. Pavkov M.E., et al. Trend
Slide 28: Sources, continued
Sources, continued 12. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2023. https://www.cdc.gov/kidney-disease/php/data-research/index.html 13. Ma X, L